Urologic Neoplasms clinical trials

The registry lists 155 studies for Urologic Neoplasms across more than 10 countries. 40 are recruiting or about to start. 54 of them are mainly about Urologic Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 8 narrower conditions too, such as Carcinoma, Renal Cell: 4,541 studies, 1,060 open.

Get an email when these change. Save the Urologic Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 65
Recruiting: 30
Terminated: 17
Active, not recruiting: 13
Status unknown: 13
Not yet recruiting: 9

Phase

Phase 2: 45
Phase 1: 29
Phase 3: 13
Phase 4: 3
Early Phase 1: 2

Where

United States: 58
France: 22
China: 16
Spain: 15
Italy: 14
Germany: 13

Who runs them

M.D. Anderson Cancer Center (10) · Eli Lilly and Company (8) · UroGen Pharma Ltd. (5) · National Cancer Institute (NCI) (5) · Hoffmann-La Roche (3) · Relmada Therapeutics, Inc. (3) · Celldex Therapeutics (2) · Seoul National University Bundang Hospital (2)

What is being tested here

Drugs under test in Urologic Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Pembrolizumab	3	1	3
Vepugratinib	2	0	2
Gemcitabine	1	0	6
Enfortumab vedotin	1	1	3
Sustained-Release Gemcitabine-Docetaxel NDV-01	1	3	3
Lenvatinib	1	0	2
SI-B036	1	0	1
Iparomlimab	1	0	1
Tuvonralimab	1	0	1
Cadonilimab	1	0	1

Drug classes tested here Immune checkpoint inhibitors 5 open · Tyrosine kinase inhibitors (TKIs) 3 open · Antimetabolites 2 open · Antibody-drug conjugates (ADCs) 1 open · Antimitotic agents 5

Coming up

5phase 3 studies under way

17studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Nov 2026A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT · Phase 3 · CG Oncology, Inc.
Nov 2026Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations · Tyra Biosciences, Inc
Nov 2026CD70-targeted immunoPET Imaging of Kidney Cancer · RenJi Hospital
Dec 2026A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors · Sichuan Baili Pharmaceutical Co., Ltd.
Dec 2026Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab · The Netherlands Cancer Institute
Dec 2026Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations · Assistance Publique - Hôpitaux de Paris
Dec 2026Web-Based Application for Monitoring Radiation Therapy Complications in Cancer Patients · Institute of Oncology Ljubljana
Jan 2027Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue · National Cancer Institute (NCI)
Mar 2027A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors · Eli Lilly and Company
Mar 2027Interest of Magnetic Resonance Imaging in the Diagnosis of Upper Urinary Tract Invasive Tumours · University Hospital, Toulouse

Who these studies take

Of the 30 Urologic Neoplasms studies recruiting now, 24 (80%) set no upper age limit and 2 (7%) stop at 75 or younger. 1 (3%) take children under 18. 1 (3%) are for women only and 4 (13%) for men only; 4 (13%) take healthy volunteers.

Recruiting studies that take each age, of 30
Age	Women	Men
10	0 (0%)	0 (0%)
18	24 (80%)	27 (90%)
30	24 (80%)	27 (90%)
40	24 (80%)	27 (90%)
50	24 (80%)	27 (90%)
65	25 (83%)	28 (93%)
75	25 (83%)	28 (93%)
85	22 (73%)	25 (83%)

Across all 155 studies, recruiting or not: 9% stop at 75 or younger and 3% at 65; 8% take children; 2% are for women only and 9% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Urologic Neoplasms studies take

Of 23 interventional studies with no phase under Urologic Neoplasms, half reached primary completion within 30 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Interventional, no phase	30 mo18–64 · 23 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Results posted1

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign DiseaseNov 5, 2026NCT01552434

Newly registered1

Hugo™ RAS Urology Post-Market Clinical StudyOct 28, 2026NCT07901049

Studies

Recruiting first, then most recently updated. Showing 50 of 155. Browse all 155 → or search them.